← Leaderboards
Craig M. Brackett
Roswell Park Cancer Institute Corp
$2,746,152
Attributed
$2,960,429
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $912.7K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,960,429 · 3
By mechanism
R01$2,103,321 · 1
R21$857,108 · 2
Top collaborators
- Scott I. Abrams2 shared
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Walter J Storkus$19,974,413
- Elizabeth Repasky$12,725,917
- Cameron Riker Macdonald$169,092
- Scott I. Abrams$11,133,748
- Richard B Bankert$9,763,302
Others in their field
Other Emerging Leaders on “Agonist”
- Julie Ake · National Institute Of Allergy And Infectious Diseases$22,000,000
- Aaron Esser-Kahn · University Of Chicago$13,378,548
- Nikej Shah · Nirsum Laboratories, Inc.$12,506,430
- Xinhua Li · Nano Terra, Inc.$11,941,250
- James Dale Berry · Brigham And Women'S Hospital$9,298,517
- James N Campbell · Centrexion Therapeutics Corporation$8,662,635
Research focus
AgonistTlr5 GeneSafetyTumor ImmunityPre-ClinicalTranslatingPublishingMediatingSignal TransductionTumorCd8-Positive T-LymphocytesImmunotherapyInnovationPharmaceutical PreparationsFlagellinImmune Checkpoint BlockadeFda ApprovedMalignant NeoplasmsNeutrophilSalmonellaInflammasomeLinkClinicHealthy Volunteer
Grant awards (7)
TLR5 enhancement of liver-directed radiotherapy plus immune checkpoint blockade against irradiated liver metastasis and abscopal tumors$705,888
R01 · FY2025 · CA · contact PI
TLR5 enhancement of liver-directed radiotherapy plus immune checkpoint blockade against irradiated liver metastasis and abscopal tumors$677,410
R01 · FY2024 · CA · contact PI
TLR5 enhancement of liver-directed radiotherapy plus immune checkpoint blockade against irradiated liver metastasis and abscopal tumors$720,023
R01 · FY2023 · CA · contact PI
Development of TLR5 agonist based approaches to boost chemo-immunotherapy by modulating immunosuppressive networks$192,653
R21 · FY2023 · CA · contact PI
Development of TLR5 agonist based approaches to boost chemo-immunotherapy by modulating immunosuppressive networks$235,901
R21 · FY2022 · CA · contact PI
Development of a Novel Immunotherapy Platform for Triple-Negative Breast Cancer$192,653
R21 · FY2022 · CA · contact PI
Development of a Novel Immunotherapy Platform for Triple-Negative Breast Cancer$235,901
R21 · FY2021 · CA · contact PI